سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ – اتجاهات الصناعة والتوقعات حتى عام 2030

Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ – اتجاهات الصناعة والتوقعات حتى عام 2030

  • Healthcare
  • Published Report
  • May 2023
  • Asia-Pacific
  • 350 الصفحات
  • عدد الجداول: 372
  • عدد الأرقام: 56

Asia Pacific Liquid Biopsy Market

حجم السوق بالمليار دولار أمريكي

CAGR :  % Diagram

Diagram فترة التنبؤ
2024 –2030
Diagram حجم السوق (السنة الأساسية)
مليون دولار أمريكي
Diagram حجم السوق (سنة التنبؤ)
USD MILLION
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>سوق خزعة السوائل في آسيا والمحيط الهادئ، حسب المنتج (الأدوات والمواد الاستهلاكية والملحقات والخدمات والبرمجيات)، نوع المنتج الحيوي ( خلايا الورم المتداولة (CTCS) ، الحمض النووي الخالي من الخلايا المتداولة (CFDNA)، الحمض النووي الريبي الخالي من الخلايا، الحويصلات خارج الخلية، الإكسوسومات، وغيرها)، نوع العينة (عينة الدم، عينة البول، عينة اللعاب وسوائل الأنسجة الأخرى، وغيرها)، النوع التحليلي (الجزيئي، والبروتينات، وعلم الأنسجة/التصوير)، نوع التطبيق (تطبيقات السرطان والتطبيقات غير السرطانية)، التطبيق السريري (الفحص الروتيني، فحص المريض، اختيار العلاج، مراقبة العلاج، مراقبة الانتكاس، وغيرها)، التكنولوجيا (التحليل المتوازي متعدد الجينات، وتحليل الجين الفردي)، المستخدم النهائي (المستشفيات، والمختبرات المرجعية، ومراكز التشخيص، ومراكز الأبحاث والمعاهد الأكاديمية، وغيرها)، قنوات التوزيع (العطاء المباشر، الموزع التابع لطرف ثالث، وغيرها) - اتجاهات الصناعة وتوقعاتها حتى عام 2030.

سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ

تحليل ورؤى حول سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ

لقد أدى الوعي المتزايد بتكنولوجيا التشخيص المتقدمة في منطقة آسيا والمحيط الهادئ إلى تعزيز الطلب على السوق. كما يساهم ارتفاع الإنفاق على الرعاية الصحية لتحسين الخدمات الصحية في نمو السوق. يركز اللاعبون الرئيسيون في السوق على إطلاق خدمات مختلفة والموافقات عليها خلال هذه الفترة الحاسمة. بالإضافة إلى ذلك، يساهم زيادة التقدم المحسن في العمليات والتقنيات أيضًا في زيادة الطلب على الخزعة السائلة.

سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئسوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ

من المتوقع أن ينمو سوق خزعة السوائل في منطقة آسيا والمحيط الهادئ في العام المتوقع بسبب زيادة عدد اللاعبين في السوق وتوافر الخدمات المتقدمة. إلى جانب ذلك، يشارك المصنعون في أنشطة التطوير لإطلاق خدمات جديدة في السوق. كما أن التطور المتزايد في مجال تقنيات الرعاية الصحية المتقدمة يعزز نمو السوق بشكل أكبر.

ومع ذلك، فإن الصعوبات مثل الافتقار إلى البروتوكولات الموحدة والافتقار إلى المتخصصين المهرة قد تعيق نمو سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ في الفترة المتوقعة.

تحلل شركة Data Bridge Market Research أن سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ من المتوقع أن ينمو بمعدل نمو سنوي مركب نسبته 13.4٪ خلال الفترة المتوقعة من 2023 إلى 2030.

تقرير القياس

تفاصيل

فترة التنبؤ

2023 إلى 2030

سنة الأساس

2022

سنوات تاريخية

2021 (قابلة للتخصيص حتى 2015- 2020)

وحدات كمية

الإيرادات بالملايين، الأحجام بالوحدات، التسعير بالدولار الأمريكي

القطاعات المغطاة

Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others)

Countries Covered

Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, and Rest of Asia-Pacific

Market Players Covered

F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Sysmex Inostics Inc., and BIOCEPT, INC. among others

Market Definition

A liquid biopsy is a medical test that involves the analysis of various biomolecules, such as DNA, RNA, proteins, and other substances in a patient's blood or other bodily fluids, to diagnose and monitor various medical conditions, including cancer. Unlike traditional biopsies that involve the removal of tissue samples from the body, a liquid biopsy is non-invasive and can provide important diagnostic information without the need for surgery or other invasive procedures. Liquid biopsies are still in the early stages of development but hold promise for improving the detection and management of cancer and other diseases.

Asia-Pacific Liquid Biopsy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below

Drivers

  • Growing demand for non-invasive liquid biopsy technique

Liquid biopsies consist of isolating tumor-derived entities such as circulating tumor cells, circulating tumor DNA, and tumor extracellular vesicles among others, present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years, as described in the review, thus providing greater details about tumor characteristics such as mutations, tumor staging, tumor progression, heterogeneity, and gene and clonal evolution, among others. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Non-invasive cancer diagnostics offer a safer and more patient-friendly approach, resulting in a growing demand for these methods.

  • Advancements in precision medicine due to liquid biopsy

Precision medical oncology in the clinical management of cancer may be achieved through the diagnostic platform called "liquid biopsy" (LB). The LB was recognized as a powerful real-time approach for the molecular monitoring of this dynamic cancer disease. This method utilizes the detection of Biomarkers in blood for prognostic and predictive purposes by non-invasive means, which in the near future will represent a change in the paradigm of molecular biology understanding and the heterogeneity of tumors. Advancements in precision medicine, fueled by the use of liquid biopsy techniques, have contributed significantly to the growing demand for non-invasive cancer diagnostics. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes in blood or other body fluids, provide valuable information about the genetic makeup of tumors, enabling precision medicine approaches in cancer care.

Opportunity

  • Integration of Artificial Intelligence (AI) and machine learning

Liquid biopsy-based approaches offer many new opportunities to measure molecular Biomakers for diagnosing, prognosis, and monitoring disease. Artificial Intelligence (AI), such as machine learning, and its ability to identify signatures of specific disease states in multiplexed data will be key to taking advantage of the new molecular information that microchip-based diagnostics can extract.

Thus, the integration of AI and machine learning is expected to act as an opportunity for the growth of the market.

  • Increasing reimbursements and government support for liquid biopsy

The adoption of liquid biopsy has been significantly influenced by government backing. Governments throughout the world have put legislation in place to encourage the adoption of liquid biopsy because they understand how it may enhance patient care, lower healthcare costs, and advance precision medicine. Incorporating liquid biopsy into national cancer screening programs or treatment recommendations is only one example of how this might be done. Other examples include financing for research and development of liquid biopsy technologies and backing clinical trials and studies to produce evidence on their therapeutic efficacy. Such government assistance has aided in boosting liquid biopsy test knowledge, adoption, and reimbursement coverage.

Thus, increasing reimbursements and government support for liquid biopsy is expected to act as an opportunity for the market's growth.

Restraint/Challenge

  • High cost of liquid biopsy tests

The liquid biopsy is severely constrained by the high cost. While liquid biopsy tests show promise for non-invasive illness detection and monitoring, including cancer, there are cost-related obstacles that may prevent their widespread use.

The necessity for specialized tools and technologies is one of the biggest economic obstacles. Costly tools, including digital PCR machines, NGS platforms, and automated sample processing systems, are frequently needed for liquid biopsy studies. Smaller healthcare facilities with tighter budgets may find it difficult to afford the initial investment and ongoing maintenance costs connected with these technologies, which limits their capacity to provide liquid biopsy tests to patients.

Thus, the high cost of liquid biopsy tests is expected to restrain the market's growth.

  • Lack of skilled professionals performing liquid biopsy

The demand for liquid biopsy tests is increasing due to their potential clinical utility in cancer detection, monitoring, and personalized treatment decision-making. However, there may be limited resources, including personnel, equipment, and funding, to support the implementation of liquid biopsy programs in healthcare institutions. This can result in a shortage of skilled professionals who can perform liquid biopsy tests, especially in regions or healthcare settings with limited resources.

Thus, the lack of skilled professionals performing liquid biopsies is expected to challenge the market growth.

Recent Development

  • In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT).

Asia-Pacific Liquid Biopsy Market Scope

يتم تصنيف سوق خزعة السوائل في منطقة آسيا والمحيط الهادئ إلى تسعة قطاعات بارزة وهي المنتج، ونوع الشركة المصنعة، ونوع العينة، والنوع التحليلي، ونوع التطبيق، والتطبيق السريري، والتكنولوجيا، والمستخدم النهائي، وقناة التوزيع. سيساعدك النمو بين هذه القطاعات على تحليل قطاعات نمو السوق في الصناعات وتزويد المستخدمين بنظرة عامة قيمة على السوق ورؤى السوق لمساعدتهم على اتخاذ قرارات استراتيجية لتحديد تطبيقات السوق الأساسية.

منتج

  • الآلات الموسيقية
  • المواد الاستهلاكية والملحقات
  • الخدمات والبرمجيات

على أساس المنتج، يتم تقسيم السوق إلى أدوات ومواد استهلاكية وملحقات وخدمات وبرامج.

نوع المنتج الحيوي

  • الخلايا السرطانية المتداولة (CTCS)
  • الحمض النووي الخالي من الخلايا المتداولة (CFDNA)
  • الحمض النووي الريبوزي الخالي من الخلايا
  • الحويصلات الخارجية
  • حويصلات خارج الخلية
  • آحرون

على أساس نوع المنتج الحيوي، يتم تقسيم السوق إلى خلايا الورم المتداولة (CTCS)، والحمض النووي الخالي من الخلايا المتداولة (CFDNA)، والحمض النووي الريبي الخالي من الخلايا، والحويصلات خارج الخلية، والحويصلات الخارجية، وغيرها.

نوع العينة

  • عينة الدم المعتمدة
  • عينة البول
  • عينة من اللعاب والسوائل النسيجية الأخرى
  • آحرون

على أساس نوع العينة، يتم تقسيم السوق إلى عينة تعتمد على الدم، وعينة تعتمد على البول، وعينة تعتمد على اللعاب وسوائل الأنسجة الأخرى، وغيرها.

النوع التحليلي

  • جزيئي
  • بروتيومية
  • علم الأنسجة/التصوير

على أساس النوع التحليلي، يتم تقسيم السوق إلى التحليل الجزيئي، وتحليل البروتينات، وعلم الأنسجة/التصوير.

نوع التطبيق

  • تطبيقات السرطان
  • التطبيقات غير السرطانية

على أساس نوع التطبيق، يتم تقسيم السوق إلى تطبيقات السرطان وتطبيقات غير السرطان.

التطبيقات السريرية

  • الفحص الروتيني
  • اختيار العلاج
  • مراقبة العلاج
  • مراقبة التكرار
  • متابعة المريض
  • آحرون

على أساس التطبيق السريري، يتم تقسيم السوق إلى الفحص الروتيني، ومتابعة المريض، واختيار العلاج، ومراقبة العلاج، ومراقبة التكرار، وغيرها.

تكنولوجيا

  • تحليل الجينات المتعددة المتوازية
  • تحليل الجين الواحد

على أساس التكنولوجيا، يتم تقسيم السوق إلى تحليل متوازي متعدد الجينات وتحليل جين واحد.

المستخدم النهائي

  • المستشفيات
  • المختبرات المرجعية
  • مراكز التشخيص
  • مراكز البحوث والمعاهد الأكاديمية
  • آحرون

على أساس المستخدم النهائي، يتم تقسيم السوق إلى المستشفيات والمختبرات المرجعية ومراكز التشخيص ومراكز الأبحاث والمعاهد الأكاديمية وغيرها.

قنوات التوزيع

  • العطاء المباشر
  • موزع الطرف الثالث
  • آحرون

على أساس قناة التوزيع، يتم تقسيم السوق إلى العطاءات المباشرة، وموزع الطرف الثالث، وغيرها.

سوق الخزعة السائلة

تحليل/رؤى إقليمية لسوق خزعة السوائل في منطقة آسيا والمحيط الهادئ

يتم تحليل سوق خزعة السوائل في منطقة آسيا والمحيط الهادئ، ويتم توفير رؤى وحجم السوق والاتجاهات بناءً على المنتج ونوع الشركة المصنعة الحيوية ونوع العينة والنوع التحليلي ونوع التطبيق والتطبيق السريري والتكنولوجيا والمستخدم النهائي وقناة التوزيع.

الدول التي يغطيها تقرير السوق هذا هي اليابان والصين وأستراليا والهند وكوريا الجنوبية وسنغافورة وإندونيسيا وتايلاند وماليزيا والفلبين وبقية دول آسيا والمحيط الهادئ.

من المتوقع أن تهيمن اليابان على سوق خزعة السوائل في منطقة آسيا والمحيط الهادئ في عام 2023 بسبب التقدم التكنولوجي في منصات خزعة السوائل في البلاد.

كما يوفر قسم الدولة في التقرير عوامل فردية مؤثرة على السوق والتغيرات في تنظيم السوق التي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. نقاط البيانات مثل تحليل سلسلة القيمة المصب والمصب، والاتجاهات الفنية، وتحليل قوى بورتر الخمس، ودراسات الحالة هي بعض المؤشرات المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية في منطقة آسيا والمحيط الهادئ والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير التعريفات الجمركية المحلية وطرق التجارة أثناء تقديم تحليل تنبؤي لبيانات الدولة

تحليل المشهد التنافسي وحصة سوق الخزعة السائلة في منطقة آسيا والمحيط الهادئ

يوفر المشهد التنافسي لسوق خزعة السوائل في منطقة آسيا والمحيط الهادئ تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور في منطقة آسيا والمحيط الهادئ، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف للشركة، وإطلاق المنتج، وخطوط أنابيب التجارب السريرية، وتحليل العلامة التجارية، وموافقات المنتج، وبراءات الاختراع، وعرض المنتج ونطاقه، وهيمنة التطبيق، ومنحنى شريان الحياة التكنولوجي. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات فيما يتعلق بسوق خزعة السوائل في منطقة آسيا والمحيط الهادئ.

بعض اللاعبين الرئيسيين في سوق خزعة السوائل في منطقة آسيا والمحيط الهادئ هم F. Hoffmann-La Roche Ltd و Guardant Health و Thermo Fisher Scientific Inc. و Exact Sciences Corporation (الصحة الجينومية) و QIAGEN و Labcorp و Johnson & Johnson Services، Inc. و Illumina Inc و NeoGenomics Laboratories و Bio-Rad Laboratories، Inc. و Natera، Inc. و CARDIFF ONCOLOGY، INC. و Sysmex Inostics Inc. و BIOCEPT، INC. من بين آخرين.


SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 INDUSTRY INSIGHTS:

6 ASIA-PACIFIC LIQUID BIOPSY MARKET, REGULATION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE

7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY

7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS

7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS

7.2 RESTRAINTS

7.2.1 HIGH COST OF LIQUID BIOPSY TESTS

7.2.2 LACK OF STANDARDIZED GUIDELINES

7.3 OPPORTUNITIES

7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING

7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY

7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES

7.4 CHALLENGES

7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY

7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES

8 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 CONSUMABLES & ACCESSORIES

8.2.1 TEST KITS

8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT

8.2.1.2 DNA ISOLATION KIT

8.2.1.3 OTHERS

8.2.2 COLLECTION TUBES

8.2.2.1 50 PIECES

8.2.2.2 100 PIECES

8.2.3 ASSAYS

8.2.3.1 FLEXIBLE REAGENTS

8.2.3.2 SCALABLE REAGENTS

8.2.3.3 OTHERS

8.2.4 CONTROL KIT

8.2.5 OTHERS

8.3 INSTRUMENTS

8.3.1 ANALYZERS

8.3.2 SYSTEMS

8.3.3 OTHERS

8.4 SERVICES & SOFTWARE

8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE

8.4.2 DPCR ANALYSIS SOFTWARE

8.4.3 CASTPCR ANALYSIS SOFTWARE

8.4.4 OTHERS

9 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE

9.1 OVERVIEW

9.2 CIRCULATING TUMOR CELLS (CTCS)

9.3 CIRCULATING CELL-FREE DNA (CFDNA)

9.4 CELL-FREE RNA

9.5 EXOSOMES

9.6 EXTRACELLULAR VESICLES

9.7 OTHERS

10 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE

10.1 OVERVIEW

10.2 BLOOD SAMPLE-BASED

10.3 URINE SAMPLE-BASED

10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED

10.5 OTHERS

11 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE

11.1 OVERVIEW

11.2 MOLECULAR

11.2.1 NGS

11.2.2 PCR

11.2.3 MICROARRAY

11.2.4 PROTEOMICS

11.2.5 OTHERS

11.3 PROTEOMIC

11.3.1 NGS

11.3.2 PCR

11.3.3 MICROARRAY

11.3.4 PROTEOMICS

11.3.5 OTHERS

11.4 HISTOLOGY/IMAGING

12 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE

12.1 OVERVIEW

12.2 CANCER APPLICATIONS

12.2.1 LUNG

12.2.2 BREAST

12.2.2.1 EARLY BREAST CANCER

12.2.2.2 ADVANCED BREAST CANCER

12.2.3 COLORECTAL

12.2.4 PROSTRATE

12.2.5 LIVER

12.2.6 OTHERS

12.3 NON-CANCER APPLICATIONS

12.3.1 PRENATAL DIAGNOSIS

12.3.2 PERSONALIZED IMMUNOTHERAPY

12.3.3 OTHERS

13 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

13.1 OVERVIEW

13.2 ROUTINE SCREENING

13.3 THERAPY SELECTION

13.4 TREATMENT MONITORING

13.4.1 EARLY-STAGE DISEASE

13.4.2 LATE-STAGE/METASTATIC DISEASE

13.5 RECURRENCE MONITORING

13.6 PATIENT WORK-UP

13.7 OTHERS

14 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY

14.1 OVERVIEW

14.2 MULTI-GENE-PARALLEL ANALYSIS

14.3 SINGLE GENE ANALYSIS

15 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 REFERENCE LABORATORIES

15.4 DIAGNOSTIC CENTERS

15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES

15.6 OTHERS

16 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 THIRD PARTY DISTRIBUTOR

16.4 OTHERS

17 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY REGION

17.1 ASIA-PACIFIC

17.1.1 JAPAN

17.1.2 CHINA

17.1.3 SOUTH KOREA

17.1.4 INDIA

17.1.5 AUSTRALIA

17.1.6 SINGAPORE

17.1.7 THAILAND

17.1.8 MALAYSIA

17.1.9 INDONESIA

17.1.10 PHILIPPINES

17.1.11 REST OF ASIA-PACIFIC

18 ASIA-PACIFIC LIQUID BIOPSY MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 GUARDANT HEALTH

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 THERMO FISHER SCIENTIFIC INC.

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 SWOT ANALYSIS

19.3.5 PRODUCT PORTFOLIO

19.3.6 RECENT DEVELOPMENTS

19.4 EXACT SCIENCE CORPORATION

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 QIAGEN

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENTS

19.6 ANGLE PLC (2022)

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 BIOCEPT, INC.

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENT

19.8 BIO-RAD LABORATORIES, INC. (2022)

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 EPIC SCIENCES

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENTS

19.1 FLUXION BIOSCIENCES INC

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENTS

19.11 ILLUMINA, INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 SWOT ANALYSIS

19.11.4 PRODUCT PORTFOLIO

19.11.5 RECENT DEVELOPMENT

19.12 JOHNSON & JOHNSON PRIVATE LIMITED

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 SWOT ANALYSIS

19.12.4 PRODUCT PORTFOLIO

19.12.5 RECENT DEVELOPMENTS

19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 SWOT ANALYSIS

19.13.4 PRODUCT PORTFOLIO

19.13.5 RECENT DEVELOPMENT

19.14 MDXHEALTH

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MENARINI SILICON BIOSYSTEMS

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENTS

19.16 NATERA, INC.

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENTS

19.17 NEOGENOMICS LABORATORIES

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENTS

19.18 ONCOCYTE CORPORATION

19.18.1 COMPANY PROFILE

19.18.2 SERVICE PORTFOLIO

19.18.3 RECENT DEVELOPMENTS

19.19 PATHAI

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENTS

19.2 PREDICINE

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENT

19.21 STRECK

19.21.1 COMPANY SNAPSHOT

19.21.2 PRODUCT PORTFOLIO

19.21.3 RECENT DEVELOPMENTS

19.22 SYSMEX INOSTICS INC.

19.22.1 COMPANY SNAPSHOT

19.22.2 REVENUE ANALYSIS

19.22.3 PRODUCT PORTFOLIO

19.22.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

List of Table

TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE

TABLE 2 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 3 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 5 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 6 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 7 ASIA-PACIFIC ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 8 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 10 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 12 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 13 ASIA-PACIFIC CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 ASIA-PACIFIC CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA-PACIFIC CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA-PACIFIC EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA-PACIFIC EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 20 ASIA-PACIFIC BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 ASIA-PACIFIC URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA-PACIFIC SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 25 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 27 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 29 ASIA-PACIFIC HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 31 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 41 ASIA-PACIFIC RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 ASIA-PACIFIC PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 ASIA-PACIFIC SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 61 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 63 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 64 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 65 ASIA-PACIFIC ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 68 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 70 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 71 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 74 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 75 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 76 ASIA-PACIFIC BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 77 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 78 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 79 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 81 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 83 JAPAN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 84 JAPAN CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 JAPAN CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 86 JAPAN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 87 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 88 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 89 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 90 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 91 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 92 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 93 JAPAN ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 95 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 96 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 97 JAPAN SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 98 JAPAN LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 99 JAPAN LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 100 JAPAN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 101 JAPAN MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 102 JAPAN PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 103 JAPAN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 104 JAPAN CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 105 JAPAN BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 106 JAPAN NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 107 JAPAN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 JAPAN TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 109 JAPAN LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 110 JAPAN LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 CHINA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 CHINA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 113 CHINA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 CHINA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 115 CHINA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 116 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 117 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 118 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 119 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 120 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 121 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 122 CHINA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 123 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 124 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 125 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 126 CHINA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 127 CHINA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 128 CHINA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 129 CHINA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 130 CHINA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 131 CHINA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 132 CHINA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 133 CHINA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 134 CHINA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 135 CHINA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 136 CHINA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 137 CHINA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 138 CHINA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 139 CHINA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 140 CHINA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 141 SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 142 SOUTH KOREA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 143 SOUTH KOREA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 144 SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 145 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 146 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 147 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 148 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 149 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 150 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 151 SOUTH KOREA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 152 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 153 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 154 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 155 SOUTH KOREA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 156 SOUTH KOREA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 157 SOUTH KOREA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 158 SOUTH KOREA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 159 SOUTH KOREA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 160 SOUTH KOREA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 161 SOUTH KOREA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 162 SOUTH KOREA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 163 SOUTH KOREA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 164 SOUTH KOREA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 165 SOUTH KOREA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 166 SOUTH KOREA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 167 SOUTH KOREA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 168 SOUTH KOREA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 169 SOUTH KOREA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 170 INDIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 171 INDIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 172 INDIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 173 INDIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 174 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 175 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 176 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 177 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 178 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 179 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 180 INDIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 181 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 182 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 183 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 184 INDIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 185 INDIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 186 INDIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 187 INDIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 188 INDIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 189 INDIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 190 INDIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 191 INDIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 192 INDIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 193 INDIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 194 INDIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 195 INDIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 196 INDIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 197 INDIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 198 INDIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 199 AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 200 AUSTRALIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 201 AUSTRALIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 202 AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 203 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 204 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 205 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 206 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 207 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 208 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 209 AUSTRALIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 210 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 211 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 212 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 213 AUSTRALIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 214 AUSTRALIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 215 AUSTRALIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 216 AUSTRALIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 217 AUSTRALIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 218 AUSTRALIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 219 AUSTRALIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 220 AUSTRALIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 221 AUSTRALIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 222 AUSTRALIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 223 AUSTRALIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 224 AUSTRALIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 225 AUSTRALIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 226 AUSTRALIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 227 AUSTRALIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 228 SINGAPORE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 229 SINGAPORE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 230 SINGAPORE CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 231 SINGAPORE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 232 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 233 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 234 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 235 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 236 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 237 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 238 SINGAPORE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 239 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 240 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 241 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 242 SINGAPORE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 243 SINGAPORE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 244 SINGAPORE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 245 SINGAPORE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 246 SINGAPORE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 247 SINGAPORE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 248 SINGAPORE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 249 SINGAPORE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 250 SINGAPORE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 251 SINGAPORE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 252 SINGAPORE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 253 SINGAPORE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 254 SINGAPORE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 255 SINGAPORE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 256 SINGAPORE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 257 THAILAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 258 THAILAND CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 259 THAILAND CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 260 THAILAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 261 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 262 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 263 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 264 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 265 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 266 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 267 THAILAND ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 268 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 269 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 270 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 271 THAILAND SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 272 THAILAND LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 273 THAILAND LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 274 THAILAND LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 275 THAILAND MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 276 THAILAND PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 277 THAILAND LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 278 THAILAND CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 279 THAILAND BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 280 THAILAND NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 281 THAILAND LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 282 THAILAND TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 283 THAILAND LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 284 THAILAND LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 285 THAILAND LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 286 MALAYSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 287 MALAYSIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 288 MALAYSIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 289 MALAYSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 290 MALAYSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 291 MALAYSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 292 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 293 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 294 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 295 MALAYSIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 296 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 297 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 298 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 299 MALAYSIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 300 MALAYSIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 301 MALAYSIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 302 MALAYSIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 303 MALAYSIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 304 MALAYSIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 305 MALAYSIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 306 MALAYSIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 307 MALAYSIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 308 MALAYSIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 309 MALAYSIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 310 MALAYSIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 311 MALAYSIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 312 MALAYSIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 313 MALAYSIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 314 INDONESIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 315 INDONESIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 316 INDONESIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 317 INDONESIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 318 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 319 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 320 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 321 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 322 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 323 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 324 INDONESIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 325 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 326 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 327 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 328 INDONESIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 329 INDONESIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 330 INDONESIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 331 INDONESIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 332 INDONESIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 333 INDONESIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 334 INDONESIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 335 INDONESIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 336 INDONESIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 337 INDONESIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 338 INDONESIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 339 INDONESIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 340 INDONESIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 341 INDONESIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 342 INDONESIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 343 PHILIPPINES LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 344 PHILIPPINES CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 345 PHILIPPINES CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 346 PHILIPPINES LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 347 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 348 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 349 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 350 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 351 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 352 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 353 PHILIPPINES ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 354 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 355 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 356 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 357 PHILIPPINES SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 358 PHILIPPINES LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 359 PHILIPPINES LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 360 PHILIPPINES LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 361 PHILIPPINES MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 362 PHILIPPINES PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 363 PHILIPPINES LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 364 PHILIPPINES CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 365 PHILIPPINES BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 366 PHILIPPINES NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 367 PHILIPPINES LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 368 PHILIPPINES TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 369 PHILIPPINES LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 370 PHILIPPINES LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 371 PHILIPPINES LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 372 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 ASIA-PACIFIC LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC LIQUID BIOPSY MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC LIQUID BIOPSY MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC LIQUID BIOPSY MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC LIQUID BIOPSY MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 ASIA-PACIFIC LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 11 THE GROWING DEMAND FOR NON-INVASIVE CANCER DIAGNOSTICS IS EXPECTED TO DRIVE THE ASIA-PACIFIC LIQUID BIOPSY MARKET GROWTH IN THE FORECAST PERIOD

FIGURE 12 CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET

FIGURE 14 ADVANTAGES OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY

FIGURE 15 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, 2022

FIGURE 16 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 17 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 18 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 19 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2022

FIGURE 20 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2023-2030 (USD MILLION)

FIGURE 21 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, CAGR (2023-2030)

FIGURE 22 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2022

FIGURE 24 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)

FIGURE 25 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2023-2030)

FIGURE 26 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2022

FIGURE 28 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2023-2030 (USD MILLION)

FIGURE 29 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2023-2030)

FIGURE 30 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2022

FIGURE 32 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2023-2030 (USD MILLION)

FIGURE 33 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, CAGR (2023-2030)

FIGURE 34 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2022

FIGURE 36 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)

FIGURE 37 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2023-2030)

FIGURE 38 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2022

FIGURE 40 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 41 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 42 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, 2022

FIGURE 44 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 45 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 46 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 48 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 49 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 50 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 ASIA-PACIFIC LIQUID BIOPSY MARKET: SNAPSHOT (2022)

FIGURE 52 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2022)

FIGURE 53 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT (2023-2030)

FIGURE 56 ASIA-PACIFIC LIQUID BIOPSY MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

Japan is expected to dominate the Asia-Pacific liquid biopsy market due to technological advancements in liquid biopsy platforms in the country.
The growth rate of the Asia-Pacific liquid biopsy market is 13.4%.
Growing demand for non-invasive liquid biopsy technique & Advancements in precision medicine due to liquid biopsy are the growth drivers of the Asia-Pacific liquid biopsy market.
Product, Biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel are the factors on which the Asia-Pacific liquid biopsy market research is based.
Major companies in the Asia-Pacific liquid biopsy market are F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Sysmex Inostics Inc., and BIOCEPT, INC. among others.